LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare Advantage coverage policy to apply Local Coverage Determination (LCD) L40205 medical necessity criteria for irreversible electroporation (IRE), the non-thermal ablation tec
Other News
FDA APPROVES GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS FOR EXPANDED USE IN FEVAR AND BEVAR
Approval brings U.S. vascular surgeons the first on-label bridging stent graft for both fenestrated and branched endovascular aortic repair, as three-year clinical outcomes demonstrate safety and effectiveness. FLAGSTAFF, Ariz., Oct. 14, 2026 /PRNewswire/ — W. L. Gore & Associates’…
Vantis Vascular Receives FDA Clearance for 6F CrossFAST Model
New 6 French model accommodates a broader range of devices while maintaining the integrated design and deliverability of CrossFAST SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ — Vantis Vascular, a medical technology company developing innovative devices for vascular interventions, today…
egnite’s Call for Science Study on M-TEER Device Durability and Long-Term Patient Outcomes to be Featured at TCT 2026
The egnite Registry contributed de-identified, longitudinal data, linking serial echocardiograms with clinical outcomes, to help answer what happens to patients after a successful mitral transcatheter edge-to-edge repair (M-TEER) procedure. ALISO VIEJO, Calif., Oct. 13, 2026 /PRNewswire/…
Sensydia Secures Oversubscribed Funding to Deliver Groundbreaking Cardiac Performance System to the Office, Hospital, and Clinic
Round of more than $6 million, led by Colle Capital Partners with support from Orlando Health Ventures, will fund completion of Sensydia’s ongoing ACOUSTIC‑1 study for the Cardiac Performance System (CPS™) and preparation for commercial launch LOS ANGELES, Oct. 13, 2026 /PRNewswire/ –…
Koya Medical to Present at October 2026 Investor Conferences
DALLAS, Oct. 13, 2026 /PRNewswire/ — Koya Medical (“Koya”), a medical technology company advancing evidence-based therapies for vascular disease, has announced its participation in two upcoming investor conferences: Goldman Sachs Healthcare Private Company Conference — Andy Doraiswamy…
Nationally Recognized Cardiac Surgeon Anthony D. Caffarelli, M.D., Joins MemorialCare as Chief of Cardiac Surgery, MemorialCare Heart & Vascular Institute
Southern California physician leader returns to Long Beach and Orange County, where his medical career began, to help advance cardiovascular care across MemorialCare. FOUNTAIN VALLEY, Calif., Oct. 12, 2026 /PRNewswire/ — MemorialCare—a leading nonprofit integrated health system in…
Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System
MINNEAPOLIS, Oct. 08, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will convene a Medical & Nursing Advisory Board on November 18–19, 2026, to support the continued development of Vivian™, the Company’s next-generation pediatric […]
Interim Real-World Results Show At-Home Subcutaneous Furosemide Can Effectively Treat Worsening Heart Failure in Patients at Imminent Risk for Hospital Admission
Gator SCALES-WHF, an investigator-sponsored study at the University of Florida, shows effective decongestion of patients at imminent risk for hospital admission with minimal user, device or safety issues; 30-day admission for treatment failure or insufficient response was rare….
SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease
LUCERNE, Switzerland and NEW DELHI, Oct. 12, 2026 /PRNewswire/ — The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary…



